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Abstract
Background: Advance care planning (ACP) is a process whereby values and goals are sensitively explored and
documented to uphold patients’ wishes should they become incompetent to make decisions in the future.
Evidenced-based, effective approaches are needed. This study sought to assess the feasibility and acceptability of
an ACP intervention informed by phase 1 findings and assessed the suitability of measures for a phase 3 trial.
Methods: Prospective, longitudinal, mixed methods study with convenience sampling. A skilled facilitator
conducted an ACP intervention with stage III/IV cancer patients and invited caregivers. It incorporated the
vignette technique and optional completion/integration of ACP documents into electronic medical records
(EMR). Quantitative and qualitative data were collected concurrently, analysed separately, and the two sets of
findings converged.
Results: Forty-seven percent consent rate with 30 patients and 26 caregivers completing the intervention.
Ninety percent of patient participants had not or probably not written future care plans. Compliance with
assessments was high and missing responses to items low. Small- to medium-sized changes were observed on
a number of patients and caregiver completed measures, but confidence intervals were typically wide and
most included zero. An increase in distress was reported; however, all believed the intervention should be
made available. Eleven documents from nine patients were incorporated into EMR. ACP may not be furthered
because of intervention inadequacies, busy lives, and reluctance to plan ahead.
Conclusions: In this phase 2 study we demonstrated feasibility of recruitment and acceptability of the ACP
intervention and most outcome measures. However, patient/family preferences about when and whether to
document ACP components need to be respected. Thus flexibility to accommodate variability in intervention
delivery, tailored to individual patient/family preferences, may be required for phase 3 research.
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Background
Decision-making in cancer care is increasingly complex
as therapeutic options increase alongside ongoing ambi-
guity about acceptable outcomes for patients with
advanced illness. Unexpected patient deterioration may
necessitate difficult conversations and ad hoc decision-
making, contributing to significant patient and family
distress [1]. Early conversations between patients,
caregivers and health professionals are encouraged to
ascertain when cancer patients may want to consider
treatment limitations to avoid inappropriate and aggres-
sive care at advanced stages of illness [2,3].
Advance care planning (ACP) is a process whereby
values and goals are sensitively explored and docu-
mented to uphold patients’ wishes should they become
incompetent to make decisions in the future [4]. ACP
conversations have broader benefits in enhancing patient
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[5] and caregiver [6] confidence, encouraging involve-
ment in health care decision-making and allowing for
consideration for additional end-of-life contingencies
whilst the patient is still competent. It is thus a core qual-
ity indicator in cancer care [7], intended to improve the
quality of death and family bereavement experiences [8].
ACP in Australia is increasingly implemented and
accepted across health and community sectors [9], with
limited uptake of advance directives, variances across
state legislation and a national framework [10] developed
to promote uniformity in practice. However, ACP in the
Australian cancer context is not routine and remains
underexplored. Its association with loss of hope [11,12],
oncologists’ reticence in initiating ACP conversations
[13,14], variances in preferences for prognostic informa-
tion [15], occasional discrepancy between patients’ and
caregivers’ desire for shared end of life (EOL) discus-
sions [6], and the iterative and dynamic nature of EOL
decision-making [16] confound healthcare workers’
considerations about optimal and timely information
provision in the cancer context.
Given challenges associated with EOL conversations
[17,18], structured interventions [19] and decision aids
[20] are encouraged to promote understanding of man-
agement options and decision-making. Decision aids for
ACP in particular allow for a systemized approach to
inform patients about care options, prompting them to
document and communicate their preferences [20].
However, studies utilizing oral and printed information,
video material, patient narratives, and case vignettes
[19,21-25] have produced varying results. A systematic
review of 55 studies assessing ACP interventions with
older adults found that patients preferred to discuss fu-
ture health care plans with family rather than healthcare
providers, complete informal (35.9%) rather than formal
(22.7%) plans, and advanced directive completion rates
improved when professional teams provided assistance
across multiple sessions [22]. Furthermore, a Cochrane
review of 131 decision aids in varied clinical contexts
demonstrated positive effects on decision-making. Com-
pared to usual care, decision aids were associated with
reduced decisional conflict and improved: knowledge of
options and their potential benefits, harms, and out-
comes; participation in decision-making; and congruence
between values and choices [26].
Yet many trials of ACP interventions or decision aids
omit preliminary investigation of clinical efficacy,
safety, recruitment potential, and resource require-
ments [21,27-29]. Given limited evidence for cancer
specific ACP interventions, a research project com-
menced in 2012 in accordance with the Medical
Research Council framework for developing complex
interventions [30]. The aim of this phase 2 study was to
assess the feasibility and acceptability of an ACP
intervention which incorporated basic principles of
local [9] and international [31,32] ACP programs as
well as findings from completed phase 1 studies [6,16].
It also aimed to assess feasibility of measures to be used
in a phase 3 trial of the intervention.
Method
Design
A prospective longitudinal mixed methods study with
convenience sampling was used [33]. The ACP inter-
vention was conducted by an experienced oncology
nurse, with post graduate training in palliative care and
many years experience conducting end-of-life conversa-
tions with cancer patients. It included a 5 step guided
process as described in Figure 1 (online - Additional file
1). Development of the ACP intervention was informed
by phase 1 findings on cancer patients’ and caregivers’
ACP related views and their recommendations for ACP
program development [6,16]. The study included pa-
tient nominated caregiver presence, and optional com-
pletion and integration of patients’ACP documents into
the hospital’s electronic medical records (EMR). ACP
documents which could be offered included an Endur-
ing Power of Attorney (Medical Treatment) (EPOAMT)
form, a researcher created ‘statement of choices’ form,
and Refusal of Treatment Certificate. An EPOAMT is
the Victorian (state of Australia) term to denote one’s
designated and lawful substitute medical decision maker
and a ‘statement of choices’ is the Australian term for
documents where people state their wishes to assist
substitute decision makers and doctors making deci-
sions on their behalf. A Refusal of Treatment Certificate
allows Victorian people to “legally refuse treatment
generally or of a particular kind for a current condition”
[9]. It also incorporated four clinical case vignettes, de-
veloped and tested in Phase 1 to initiate and support
ACP discussions [6,16]. The clinical vignettes were used
within the intervention to highlight circumstances
where an ACP could assist families and professionals
with appropriate end-of-life conversations and patient
care decisions. Vignettes are useful when exploring sen-
sitive issues [34] to assist participants reflect from a less
threatening third person perspective and to introduce
personal experiences when desired [35].
Participants and setting
This study was conducted at a large specialist oncology
facility in Australia. Participants were recruited from the
lung, gastrointestinal, sarcoma, head and neck and
urological streams between February and July 2013.
Ethics approval was obtained from the Peter MacCallum
Cancer Centre’s Human Research Ethics Committee.
Recruitment was limited to English speaking cancer
patients and caregivers 18 years or older, previously
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unknown to the intervention facilitator and research
interviewer, and had not participated in the phase 1
studies. Patients also had stage III/IV disease, prognosis
of > 6 weeks, and Australian Karnofsky Performance
status > 40.
Study procedure
The study procedure, measures used, and brief descrip-
tion of the intervention are in Figure 1. A detailed
description of the ACP intervention is available online
(Additional file 1).
Mailed Pre-baseline/T1 questionnaire pack to consenting participants 
Patient pre-baseline pack 
Patient information sheet on ACP, EQ-5D-3L,1 FACT-G,2 Modified Lyons ACP Survey,3 PPAIQ,4
QPCCS5 
Caregiver pre-baseline pack 
Caregiver information sheet on ACP, PPAIQ
Approached eligible participants 
Trained ACP facilitator (AB) approached eligible participants by telephone or in person. 
Interested participants provided with Participant Information and Consent Form. 
Obtained formal consent 
Scheduled date for Baseline/T2 assessment and ACP intervention 
Baseline/T2 assessment and ACP intervention 
Patient completed DCS6 and ACP intervention administered by trained facilitator. The intervention included 
1. Identifying and exploring gaps in knowledge and understanding of ACP 
2. Eliciting understanding of the role of ACP in cancer 
3. Tailoring the intervention to address unique decision-making needs and preferences 
4. Supporting the actualisation of an advance care plan 
5. Summarising interview and assessment for additional support
Pre-baseline/T1 assessment 
Pre-baseline questionnaires for patients and caregivers completed before first research meeting. 
1 week post-intervention/T3 assessment 
Senior researcher conducted and audio-taped semi-structured interviews (see Supplemental Appendix S1) with patients and 
caregivers separately to obtain a comprehensive summary of their ACP understanding, views about the intervention and 
related thoughts, conversations and actions since the intervention. 
Patient completed DCS 
4 weeks post-intervention/T4 assessment 
Patient and caregivers completed 4 weeks post-intervention questionnaires in phone 
interview with senior researcher 
Patient: EQ-5D-3L, PPAIQ, QPCCS, DCS 
Caregiver: PPAIQ
System check list to be completed 
ACP facilitator recorded the number and nature of written ACP components completed, including medical enduring power of attorney, 
statement of choices and refusal of treatment documents. ACP section in EMR was updated. 
Identified eligible participants 
1. Euroqual (EQ-5D-3L)
Measures health outcomes applicable to a wide range of health conditions and treatments and covers the domains of mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression and a VAS recording respondents’ self-related health.  
2. The Functional Assessment of Cancer Therapy (FACT-G version 4)56 
 A general quality of life instrument validated in the general cancer population. It encompasses physical, social/family, emotional and functional well-being. 
3. The Lyon ACP Survey
This survey was modified from its original to gather information about whether and how patients have considered, discussed, and/or completed ACP components. 
4. Pre-post ACP Intervention VAS Questionnaire (PPAIQ)  
The questionnaire, designed by the researchers, comprised 9 (patient) or 8 (caregiver) items, exploring understanding and perspectives on ACP, rated on a scale of 0-10 
anchored by word descriptors at each end.  
5. Quality of Patient-Clinician Communication Scale (QPCCS)
Assessed quality of patient-clinician communication about end-of-life care clinicians listening skills, attentiveness, care and understanding of EOL treatment preferences.   
6. Decision Conflict Scale (DCS)
Measures personal perceptions about uncertainty in choosing options, factors which contribute to the uncertainty, and the effectiveness of one’s decision-making. 
Figure 1 Study schema [56].
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Sample size
The pragmatic sample size of thirty patient-caregiver
dyads was expected based on Phase 1 recruitment [6,16]
and funds available.
Analysis
Quantitative and qualitative data were collected concur-
rently, analysed separately, and the two sets of findings
converged [36].
Statistical analysis
All quantitative analysis was performed through SPSS
Windows Version 21.0 [37]. Prior to formal analysis,
descriptive statistics and graphical displays were used
to identify missing values and to examine the data
distribution. Descriptive statistics were also used to
summarise characteristics relevant to participant flow,
compliance with assessments and questionnaires, pre-
baseline participant characteristics (patients and care-
givers) and responses to study measures.
For the Euroqual-5D (EQ-5D-3L) [38] and Pre-post
ACP Intervention Questionnaire (PPAIQ), paired-
samples t-tests were used to calculate estimates of
change at T4 from T1 with 95% confidence intervals.
Analysis of the Decisional Conflict Scale (DCS) [39]
was carried out by fitting a linear mixed model to all
available data. A reference cell model was used to esti-
mate mean changes from T2 at follow-up assessment
with 95% confidence intervals [40]. The mixed model
was estimated by maximum likelihood and an unstruc-
tured covariance type was used to model the covari-
ance structure among repeated measures. Effect size
(ES) estimates were calculated to characterise the size
of before and after changes [41]; these were inter-
preted as per Cohen’s d (0.2, small; 0.5, medium; and
0.8, large change) [42].
Qualitative analysis
Analytic strategies were derived from grounded theory
methods [43]. Patient and caregiver transcribed inter-
views underwent inductive, cyclic and constant com-
parative analysis. Initially, patient and caregiver data
were separately coded and comparable codes grouped
into sub-categories. Patient and caregiver sub-categories
were then compared and grouped into categories. Com-
parable categories were grouped into themes. Qualitative
data management software was used [44]. Initial analysis
was conducted by CO with subsequent inter-rater
reliability [45] provided by NM and AB.
Results
Trial profile
Of 127 patients eligible for the study (Figure 2), 64 were
approached and 30 consented (47% consent rate)
between February and July 2013. Insufficient research
personnel resulted in 63 eligible patients not being
approached. Twenty-six caregivers also consented. One
patient did not have a caregiver, one caregiver declined,
and two could not attend the intervention. Patient and
caregiver baseline characteristics are summarised in
Table 1.
Need for intervention
Modified Lyon ACP [46] survey responses assessed at
baseline are summarised in Table 2. Seventy percent had
not written and 20% had probably not written about
future health plans. Few (7%) had heard about and com-
pleted an ACP. At least 67% had not completed an
EPOAMT and had never discussed their wishes for care
at the EOL.
Intervention fidelity and characteristics
All 30 patients completed the ACP intervention, includ-
ing 26 with nominated caregivers. Seventeen interven-
tions were completed at the specialist oncology facility
(9 outpatients, 5 inpatients, 3 in day chemotherapy unit)
and 13 at patients’ homes. Mean ACP intervention com-
pletion time was 44 (SD 9) minutes.
Compliance with assessments and questionnaires
Apart from 1 week post-intervention/T3 (77%), compli-
ance with assessments was high for patients (≥87%)
and caregivers (≥92%). Missing responses to items com-
prising each questionnaire was very low for patients
(<2.5%) and caregivers (<1.0%).
Estimate of change
Descriptives for study measures EQ-5D-3L and DCS,
completed by patients at pre-baseline, baseline and
follow-up assessments, are in Table 3. Descriptives were
not calculated for the Quality of Patient-Clinician
Communication Scale (QPCCS) [47] due to the high rate
of missing data. Descriptives for study measures com-
pleted by caregivers are available from the authors.
Estimates of change and effect size for study measures
completed by patients only (EQ-5D-3L, DCS) and by pa-
tients and caregivers (PPAIQ) are in Table 4.
a) Decision conflict scale (DCS)
For patients, an improvement of 4.7 points (95% CI: −11.6,
2.2; ES = 0.29) was observed on the DCS Total score,
indicating lower decisional conflict at 4 weeks post-
intervention. Taking into consideration the rescaling of
summed responses to items comprising the DCS Total
score, this is the equivalent of about a 1-point change of
improvement on any three DCS items (or, alternatively, a
3-point change of improvement on one item). In terms of
DCS sub scores, the magnitude of change was greatest for
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values clarity (ES = 0.39), support (ES = 0.32) and uncer-
tainty (ES = 0.31), reflecting small-sized improvements
in clarity, perceived support in decision-making, and
certainty about a better choice being made.
b) Pre-post ACP intervention questionnaire (PPAIQ)
Patients’ responses to questions 1 and 2 of the PPAIQ indi-
cated medium-sized improvements of 1.2 (95% CI: −0.02,
2.3; ES = 0.50) and 1.1 (95% CI: −0.01, 2.2; ES = 0.58) points
by 4 weeks post-intervention in understanding of ACP
and satisfaction associated with opportunities to
consider possible future health care needs and wishes
with health care professionals. An increase of 1.1 points
(95% CI: 0.2, 2.0; ES = 0.50) was also observed on ques-
tion 3 at the last follow-up, indicating a medium-sized
increase in patients’ level of distress associated with
thinking about possible future health care needs and
wishes if they became unwell.
Figure 2 CONSORT participant flow.
Michael et al. BMC Palliative Care Page 5 of 12
Caregivers’ responses to question 2 indicated a large-sized
improvement of 1.9 points (95% CI: 0.8, 2.9; ES = 0.83) by
4 weeks post-intervention in satisfaction associated with
opportunities to consider possible future health care needs
and wishes with health care professionals. A medium-sized
improvement of 1.6 points (95% CI: 0.2, 3.0; ES = 0.56) was
also observed on question 6, indicating greater confidence in
discussion of possible health care needs and wishes with
health professionals.
Integration of ACP into EMR
Thirty patients were offered ACP documents to complete,
28 accepted them. Participants were invited to return pre-
viously or recently completed documents for scanning
into the EMR. Eleven documents from 9 patients were
returned which included 6 statements of choices and 5
EPOAMT.
Participation in follow up interview 1 week
post-intervention
Most patients (23/30) and caregivers (25/26) participated
in the 1 week post-intervention semi-structured inter-
view. Non-participation reasons were: unable to contact
(2 patients; 1 caregiver); too unwell (5 patients). Mean
patient interview time was 22 (SD 9) minutes and mean
caregiver interview time was 21 (SD 9) minutes.
Three themes addressing feasibility and acceptability
were identified:
An ACP intervention may motivate participants to
consider, actualise, or alter existing ACP’s
The ACP intervention initiated or extended many
patients’ thoughts and discussions about their future
health care desires should they lose their ability to state
their views in the future. These discussions could be
conducted with caregivers, other family members, and
health professionals. Some caregivers especially wel-
comed becoming more aware of patients’ EOL care
desires. One recently married 42-year-old caregiver was
shocked to hear her husband’s preference to die in
hospital because the patient remained distressed by
memories of caring for his first wife who died from can-
cer and he did not want her “completely drained” by
care-giving. Following the intervention she told him, “‘I
Table 1 Participant characteristics
Patients Carers





Male 19 63 8 31
Female 11 37 18 69
Marital status
Single 3 10 4 15
Married 19 63 15 58
Defacto/living together 5 17 5 19
Separated/divorced 1 3
Widowed 2 7 2 8
Place of birth
Australia 20 67 19 73
Not Australiaa 10 33 7 27
Time in Australia, if not
born in Australia
Mdn 36.5 39.0
IQR [22.3, 46.3] [14.0, 50.0]
Preferred language
English 29 97 26 100
Other 1 3
Highest level of education
Less than high school 5 17 9 35
High school graduate 6 20 8 31
TAFE/University degree 13 43 6 23
Post-graduate degree 6 20 3 12
FACT-Gb
Physical wellbeing 17.8 (5.5)
Social wellbeing 21.0 (4.3)
Emotional wellbeing 16.6 (4.9)
Functional wellbeing 16.0 (5.1)










Table 1 Participant characteristics (Continued)




aNot Australia includes England (2 patients, 3 carers), Greece (1 patient), Hong
Kong (1 patient, 1 carer), Ireland (1 patient), Italy (1 patient), Malta (1 patient, 1
carer), New Zealand (2 patients, 1 carer), Scotland (1 patient) and Sweden
(1 carer).
bEstimates for FACT-G are means (and standard deviations).
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made a promise that I would look after you’ …, he did
hug me and say, ‘I know but I also know how awful it
can be’, … it’s unfinished business.”
Patients’ and caregivers’ can find the acceptable
intervention reassuring, supportive, confronting or
disempowering
Many participants said that the intervention helped
them to feel respected, heard, valued, empowered, and
relieved. A 69-year-old husband caregiver said that ACP,
“lifts a huge burden from a caregiver”. Important infor-
mation sharing could also result. A 38-year-old daughter
added that her father had only shown “bravado” since
his illness whereas after the “really helpful” intervention,
“He finally talked about, you know, being worried about
leaving his kids,… not being around to see his grandchil-
dren, … prognosis.”
Some found the intervention both informative and dis-
tressing. One couple first considered that the patient
may not recover during the intervention. A 64-year-old
patient said, “It puts you on a dead end, … it was con-
fronting but on the other hand, just, you have to make a
decision.”
Occasional participants feared ACP implied that
patients were close to death. A 65-year-old patient
“physically had to be sick” after the intervention, add-
ing, “It really knocked me to think that I’m being put in
that pigeon hole. I mean I want to live …. It’s bad
enough me having to retire.” However, this patient
thought that ACP should be an available option, as did
all study participants.
Patients and caregivers usually welcomed partaking in
the intervention together, with many patients stating
that they would not complete it alone. It occasionally,
however, exposed family tension. One 68-year-old care-
giver felt that her attitudes remained disrespected
following the intervention, adding that conversations
with her husband are, “always punctuated with what he
wants”. Another 52-year-old male patient reflected on
challenges of potential caregiver role reversal with his
mother. Although he thought she, “would have a pretty
good idea of what I would want anyway without it being
put down” his mother expressed concern that he,
“doesn’t talk to me” and that his ACP related affairs
were “left in limbo”.
ACP components may not be furthered post
interventions
The reasons for why the majority of patients did not
complete any written components of ACPs following the
intervention were variable. These included patients and
caregivers: not feeling ready or interested in ACP; con-
sidering their exiting plans as sufficient; and believing
that “you can’t plan ahead”. Many had busy lives which
involved dealing with the patients’ illnesses and some
found the intervention inadequate. Two participants
who were also physicians wanted to convey more spe-
cific medical details about their care and considered the
documents as inadequate for these purposes. A 32-year-
old male said, “It was more of an introduction .... I prob-
ably wasn’t too sure about how to proceed further.”
Discussion
The challenge of conducting research in patients with
advanced illness is well established [48]. Our results
however established the feasibility of an ACP interven-
tion specifically developed for cancer patients with
stage III/IV disease, demonstrating a high compliance
Table 2 Modified Lyons ACP survey responses
Item n %
Have you ever written down any thoughts about your future
health plans?
Yes, definitely 1 3.3
Very probably 1 3.3
Probably 1 3.3
Probably not 6 20.0
Definite no 21 70.0
Don't know
Advance Care Plans allow people to make their health care
choices known before becoming seriously ill.
Have heard about and completed 2 6.7
Have heard about but not completed 13 43.3
Have not heard about 13 43.3
Don't know 2 6.7
Have you ever heard about and completed a Medical
Enduring Power of Attorney in which you name someone to
make decisions about your health care in case you could not?
Have heard about and completed 8 26.7
Have heard about but not completed 14 46.7
Have not heard about 6 20.0
Don't know 2 6.7
Whether you have completed any Advance Care Planning or







Primary physician 1 3.4
Clergy 1 3.4
Other 7 24.1
Have not talked with anyone 12 41.4
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with the intervention, assessments and questionnaires.
The QPCCS [39], however, was often unanswerable
because many patients had not engaged in EOL discus-
sions with physicians. Following the intervention,
participants chose the extent to which they considered,
discussed, or wrote down future plans, if at all. Only 9
patients submitted ACP documents for integration into
EMR during the 4 week data collection phase, reinfor-
cing that cancer patients often need time to approach
ACP and may not be suited to interventions expecting
document completion, especially if required within a
short time-frame. While some emphasized their disin-
terest in ACP, all believed that the intervention should
be available. The intervention occasionally elicited pre-
existing tension between patient/caregiver, however,
there was no causal evidence. Although participants’
regular, positive accounts of the intervention’s effect
affirmed its broad acceptability, caution is needed
because one participant became distressed and over
half declined study involvement.
Table 3 Descriptives for study measures completed by patients at pre-baseline, baseline and follow-ups
Study measure
Assessment




n M SD n M SD n M SD n M SD
EQ-5D
Visual Analogue Scale (0=worst imaginable to 100=best imaginable
health state)
29 60.6 19.1 26 69.9 20.0
Pre-post ACP Intervention Questionnaire
1. I rate my current understanding of ACP as (0=poorest to 10=best
possible understanding)
30 6.5 2.4 26 7.6 1.8
2. The opportunity to consider my possible future health care needs and
wishes with health care professionals have been as (0=unsatisfying to
10=satisfying as possible)
27 6.8 2.2 25 8.0 1.5
3. Thinking about my possible future health care needs and wishes if I
became unwell causes me (0=lowest to 10=highest distress
imaginable)
30 3.4 2.2 26 4.6 2.7
4. Discussing my possible future care health needs and wishes with
others would cause me the (0=lowest to 10=highest distress
imaginable)
30 3.6 2.6 26 3.8 2.5
5. Making and informing others about decisions related to my possible
future health care needs and wishes is (0=not important at all to
10=extremely important)
30 7.8 1.8 26 8.4 1.9
6. My confidence in discussion of my possible future health care needs
and wishes with health professionals is (0=lowest to 10=highest
possible)
30 7.7 2.2 26 8.4 1.3
7. My confidence in discussion of my possible future health care needs
and wishes with family members/friends is (0=lowest to 10=highest
possible)
30 8.0 2.2 26 8.4 1.7
8. Considering my advanced care plan is (0=not helpful at all to
10=extremely helpful)
30 7.8 2.0 26 8.0 2.7
9. Considering advance care planning when living with a cancer
diagnosis is (0=not important at all to 10=always important)
30 8.0 1.9 26 8.6 2.3
Decision Conflict Scale
Total score (0=no to 100=extremely high decisional conflict) 30 23.9 16.5 22 22.0 15.3 26 19.7 15.9
Uncertainty subscore (0=extremely certain to 100=extremely uncertain
about best choice)
30 28.9 23.6 23 27.2 21.6 26 22.4 21.4
Informed subscore (0=feels extremely informed to 100=feels extremely
uninformed)
30 22.2 17.4 22 24.2 23.6 26 19.9 16.8
Values clarity subscore (0=feels extremely clear to 100=feels extremely
unclear about personal values for benefits & risks/side effects)
30 29.4 19.4 22 27.7 22.9 26 22.1 16.7
Support subscore (0=feels extremely support to 100=feels extremely
unsupported in decision making)
30 20.3 16.2 22 14.4 12.4 26 15.7 15.5
Effective decision subscore (0=good decision to 100=bad decision) 30 20.0 17.4 23 18.8 11.8 26 18.5 17.9
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The modified Lyons [46] survey findings demonstrate
poor pre-existing knowledge and actualisation of ACP.
This was not unexpected given that the authors initiated
this research programme to complement ongoing state-
wide and national initiatives to promote ACP [10,49]. In
keeping with prior studies [24,50], small-sized changes,
reflecting improvement, were observed in decisional
conflict, with improved clarity, perceived support in
decision-making, and certainty about a better choice
being made observed. Nonetheless, confidence intervals
for estimates of change were wide and all included zero.
Small to medium-sized changes were also observed in:
patients’ understanding and satisfaction with opportun-
ities to consider future health care needs; and caregivers’
confidence in discussions with health professionals.
Again, confidence intervals were wide and most included
zero. A large-sized change was observed in caregivers’
satisfaction with opportunities to consider patients’
future health care needs. Patients’ distress associated
with thinking about ACPs four weeks post intervention
reinforces that ACP can remain difficult for cancer
patients even when its benefits are acknowledged [16].
Updated guidance for the evaluation of complex inter-
ventions [30] such as ACP promotes theoretical develop-
ment and early phase piloting as we have done. We used
a combination of methods: the vignette technique, a
guided intervention by a skilled facilitator and a mixed
methods research approach to allow for an integration
of process and outcome evaluation [51]. In view of the
ethical implications of including a control group in ACP
intervention research with patients with advanced ill-
nesses [52], future phase 3 studies require consideration
beyond that of a standard randomized design to possibly
include a stepped wedge design, high quality quasi ex-
perimental or observational study designs. Furthermore,
given that phase 1 findings illustrated how ACP needs to
be offered in a flexible, individualized and patient- and
family-centered manner in oncology [6,16], fidelity of re-
lated interventions need to accommodate unsystematic
variations in intervention delivery. For example, this
Table 4 Estimates of change and effect size for study measures completed patients (EQ-5D-3L, DCS and PPAIQ) and
carers (PPAIQ)
EQ-5D-3L (patients only) M chg T1 to T4 (95% CI) ES
Visual Analogue Scale 6.1 (-.1, 12.3) 0.36
Decision Conflict Scale (patients only) M chg T2 to T3 (95% CI) ES M chg T2 to T4 (95% CI) ES
Total score -1.2 (-7.1, 4.8) 0.07 -4.7 (-11.6, 2.2) 0.29
Uncertainty subscore -2.5 (-11.7, 6.6) 0.11 -7.1 (-16.3, 2.2) 0.31
Informed subscore 3.4 (-4.4, 11.3) 0.2 -2.5 (-11.1, 6.1) 0.15
Values clarity subscore -1.0 (-11.6, 9.6) 0.05 -7.4 (-16.8, 1.9) 0.39
Support subscore -5.2 (-10.4, 0.03) 0.33 -5.1 (-11.3, 1.0) 0.32
Effective decision subscore -1.2 (-6.2, 3.8) 0.07 -1.9 (-8.8, 4.9) 0.11
Patients Carers
Pre-post ACP Intervention Questionnaire (patients and carers) M chg T1 to T4 (95% CI) ES M chg T1 to T4 (95% CI) ES
1. I rate my current understanding of ACP as … 1.2 (-0.02, 2.3) 0.50 1.0 (0.1, 1.9) 0.40
2. The opportunity to consider my possible future health care needs and
wishes with health care professionals have been as …
1.1 (-0.01, 2.2) 0.58 1.9 (0.8, 2.9) 0.83
3. Thinking about my possible future health care needs and wishes if I
became unwell causes me …
1.1 (0.2, 2.0) 0.50 .5 (-0.7, 1.7) 0.19
4. Discussing my possible future care health needs and wishes with
others would cause me the …
0.3 (-0.4, 1.1) 0.14 .5 (-0.8, 1.9) 0.21
5. Making and informing others about decisions related to my possible
future health care needs and wishes is …
0.6 (-0.3, 1.4) 0.30 .2 (-0.3, 0.6) 0.19
6. My confidence in discussion of my possible future health care needs
and wishes with health professionals is …
0.4 (-0.3, 1.2) 0.21 1.6 (0.2, 3.0) 0.56
7. My confidence in discussion of my possible future health care needs
and wishes with family members/friends is …
0.4 (-0.1, 0.9) 0.19 0.5 (-0.3, 1.4) 0.33
8. Considering my advanced care plan is … 0.2 (-0.9, 1.2) 0.08 -0.08 (-0.6, 0.5) 0.06
9. Considering advance care planning when living with a cancer
diagnosis is …
0.5 (-0.04, 1.0) 0.25 1.0 (0.1, 1.9) 0.40
M chg: mean change, T1: pre-baseline, T2: baseline, T3: 1 week post-intervention, T4: 4 weeks post-intervention, ES: effect size.
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may involve the incorporation of the ‘Technology
Model’, which includes monitoring of the intervention,
accompanying procedures manual development, training
and monitoring of interventionist as well as ongoing
recording of variations in intervention delivery [53].
Several issues were identified that will require revision
for a larger study. We only achieved a 47% consent rate,
which was significantly lower than another ACP study
which examined the impact of ACP amongst elderly
Australians with nonmalignant conditions [29] and
oncology studies in which oncologists recruited partici-
pants [21,28], while compatible with other oncology
studies with researcher or nurse recruitment [5,6,16,54].
Recruitment by medical practitioners may increase
consent rates though potential participants may feel less
coerced when invited by non-clinical researchers or
nurses. Follow up intervals warrant reconsideration as
eight cancer patients were too sick to complete follow
up due to the demanding schedule of treatment and
declining illness trajectory. Cancer patients with stage I-
II disease should be invited to participate in future
studies with opportunities to revisit ACP decisions.
There are numerous study limitations. The study is
highly vulnerable to selection bias as it was conducted in
a single quaternary cancer centre which treats a cohort
of treatment avid cancer patients, many of which are on
early phase clinical trials. A small budget limited the
intervention to a single point of contact, contrary to
recommendations that suggest that uptake is increased
when patients have multiple interactions with staff pro-
viding information [22]. We also did not elicit reasons
for the low number of ACP documents submitted for in-
clusion to the EMR. However, as described in previous
studies, some may have chosen to reject or relinquish
ACP; may have required more time to consider ACP
and may prefer informal conversations over completion
of formal documentation [6,16,22]. Finally, the facilitator
was an experienced and confident member of the
nursing team which may have positively influenced the
intervention’s acceptability. A 58-year-old male patient
stated, “Researcher was great to talk with, easy to talk
with, she let you sit back and have your say,” and a 60-
year-old female caregiver said, “She explained it really,
really well, and she put me at ease, and I felt very happy
to be involved in the program”.
Conclusion
An ACP intervention for advanced cancer patients and
their caregivers was developed from phase 1 data and
delivered by an experienced nurse. Feasibility of recruit-
ment and acceptability of the intervention and most out-
come measures were demonstrated. Modification of the
intervention, incorporation of the Technology Model
and further resourcing will be required for a larger
study. Although the intervention elicited many helpful
EOL conversations, our studies have demonstrated that
repeated invitations for participation in ACP may elicit
distress in some patients and many patients continue to
be reticent about completing formal ACP documentation
[6,16]. We continue to advocate for the ethical principal
of “respect for persons” [55] over patient autonomy in
view of the distinct variability in patients’ wishes to be in-
volved in end-of-life discussions and decision making.
The results from this study support the notion that ACP
should be offered to all patients with advanced cancer
and tailored to their individual preferences, rather than
rigidly enforced.
Additional file
Additional file 1: ACP intervention.
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